

CURRICULUM VITAE OF ANGELO ARMANDI

E-mail: angelo.armandi@unito.it

Work address: A.O.U. Città della Salute e della Scienza di Torino, Corso Bramante 88/90, 10126 Torino, Italy

Education:

- February – April 2021: Advanced Course in Systematic Reviews and Meta-analysis at University of Milan, Italy
- April 2021: Echosens Certificate in Transient Elastography Operator for liver and spleen stiffness with Fibroscan F630 Expert
- 2016: Degree in Medicine and Surgery at University of Bari, Italy, with vote 110/110 cum laude
- 2010: High School Diploma in Classical Studies with vote 100/100 cum laude

Work experience:

- Member of the European Association for the Study of the Liver (EASL) and of the Italian Association for the Study of the Liver (AISF)
- 2022: Guest Editor for “Frontiers in Endocrinology” Journal with the Research Topic “Non-Alcoholic Fatty Liver Disease Across Endocrine Diseases: From Pathophysiology to Novel Therapeutic Approaches”
- 2022 – current: teaching activity (Collaboratore alla Didattica) at the Nursing Degree Course of the Azienda Sanitaria Locale Torino, University of Turin; supporting teaching and tutoring activity at the School of Medicine of the University of Turin
- 2021 – current: PhD Candidate in Medical Pathophysiology at University of Turin (XVII Cicle), with a research project entitled: “Metabolic mechanisms of liver fibrosis progression and non-invasive biomarkers of fibrosis in Non-Alcoholic Fatty Liver Disease”
- Member of the Editorial Board of “Frontiers in Hepatology” as Review Editor
- Reviewer for the following journals: Digestive and Liver Disease, JHep Reports, Liver International, Hepatology
- February 2021 - current: fellow at the University Medical Center of Mainz and member of the Metabolic Liver Research Program led by Prof. Jörn M. Schattenberg. Research activity on novel fibrogenesis markers in cooperation with the Institute for Translational Immunology led by Prof. Detlef Schuppan. Conceptualization of experimental protocols for the non-pharmacological treatment of Non-Alcoholic Fatty Liver Disease (NAFLD). Diagnostic and prognostic role of spleen stiffness measurement in chronic compensated advanced liver disease and portal hypertension.
- 2019 – current: Sub-Investigator of clinical trials with investigational products for the treatment of Non-Acoholic Steatohepatitis (NASH) and fibrosis
- 2018 – current: research activity at the Gastroenterology and Molecular Hepatology Laboratory led by Prof. Elisabetta Bugianesi. Participation to national and international projects on pathogenesis, diagnosis and management of NAFLD. Participation to TESEO (Traguardi di Eccellenza nelle Scienze mediche Esplorando le Omiche) Project- MIUR Dipartimenti di Eccellenza of the Department of Medical Sciences, University of Turin. Participation to European

Project LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis). Research activity focused on the study of non-invasive biomarkers of liver injury; exploration of the gut-liver axis and the relationship between gut microbiota, chronic intestinal disorders and liver disease; role of sarcopenia in patients with dysmetabolic liver disease

- 2017 – 2021: School of Residency in Digestive Diseases of the University of Turin, led by Prof. Giorgio Saracco. Inpatient and outpatient activity for upper and lower digestive tract diseases, liver and pancreatic diseases. Digestive Ultrasound and Hepatocellular Carcinoma outpatient activity. Liver Intensive Care Unit and Liver Transplant outpatient activity. Upper and Lower Digestive Endoscopy. Final Thesis: “C-peptide as novel biomarker for the detection of liver fibrosis and fibrosing Non-Alcoholic Steatohepatitis in individuals with biopsy-proven Non-Alcoholic Fatty Liver Disease”. Vote 70/70 cum laude and press dignity.

Abstract presentations, given speeches and awards

- Innovations in NAFLD Care Workshop 2023; oral presentation “Time restricted feeding for the management of Non-Alcoholic Fatty Liver Disease: interim analysis from a randomized, placebo-controlled interventional study”. Barcelona, 27 May 2023

- United European Gastroenterology Week 2022; moderated poster presentation “The use of spleen stiffness measurement for the detection of high-risk esophageal varices in patients with portal hypertension”. Vienna, 11 October 2022

- EASD EGIR & NAFLD Study Group 2021; oral presentation “Irisin alleviates oxidative stress in non-obese, non-diabetic individuals with Non-Alcoholic Fatty Liver Disease”. Virtual Meeting, 7 December 2021

- EASL ILC 2021; oral presentation: “Increased serum ferritin levels predict long-term mortality in patients with Non-Alcoholic Fatty Liver Disease”. Virtual Meeting, 23-26 June 2021

- Verbania, October 20th 2023: lecture at the Congress "XV incontro piemontese in endocrinologia, diabetologia e metabolismo" with a presentation entitled: "Complicanze epatiche dell'obesità: NAFLD/NASH"

- Copenhagen, October 14th - 17th 2023: Junior Chair at the session "Mechanisms and treatment of steatotic liver" at the UEG Week 2023

- Copenhagen, October 14th - 17th 2023: Expert Panel of the Clinical Case Discussion section on Spontaneous Bacterial Peritonitis

- Turin, June 16th 2023: lecture at the Congress "Casi clinici multidisciplinari nelle malattie infiammatorie croniche intestinali: terapie tradizionali e a bersaglio molecolare" with a presentation entitled: "Complicanze epatologiche in IBD"

- Turin, October 3rd 2023: lecture at the Congress "PBC ed epatopatie autoimmuni ad impronta colestatica" with a lecture entitled: "Prospective validation of LSM in PBC patients"

- March, 17th 2023: lecture at the Symposium "Update on Fatty Liver Disease management: beyond 2021 AIF guidelines" of the AIF Annual Meeting (Rome) with a presentation entitled "An update on NASH drug pipeline"

- Scuola di Microbioma 2022; speaker: “Steatosi, steatoepatite e microbioma”. Turin, 7 October 2022

- EASL ILC 2022; case presenter “EASL-EASD Board Session: One or many fatty liver diseases? Clinical impact of disease heterogeneity”. London, 23 June 2022

- Award winner of the UEG Research Fellowship 2023 with the project: “Immune activation and the liver-spleen axis in Non-Alcoholic Steatohepatitis”
- United European Gastroenterology Week 2022, Best Abstract Presentation Prize for the abstract presentation in the moderate poster “The pressure is on: portal hypertension”. Vienna, 11 October 2022
- 2022 – current: Gastroenterology Bursary award entitled “Meccanismi cellulari e molecolari di danno epatico in pazienti con Non-Alcoholic Steatohepatitis (NASH)” at the Gastrointestinal and Hepatology Unit of the University Hospital “Città della Salute e della Scienza di Torino”

Scientific production

Author of 69 publications indexed on Medline; H-index 13 (Scopus). ORCID: 0000-0002-7245-4445.

Most relevant publications in the hepatology field:

- Armandi A, Merizian T, Werner MM, et al. Variability of transient elastography-based spleen stiffness performed at 100 Hz. *Eur Radiol Exp* 2023; in press.
- Petroni ML, Colosimo S, Brodosi L, Armandi A, Bertini F, Montesi D, Bugianesi E, Marchesini G. Long-term follow-up of web-based and group-based behavioural intervention in NAFLD in a real world clinical setting. *Aliment Pharmacol Ther.* 2023 Oct 16.
- Armandi A, Michel M, Gjini K et al. Emerging concepts in the detection of liver fibrosis in non-alcoholic fatty liver disease. *Expert Rev Mol Diagn.* 2023 Jul-Dec;23(9):771-782.
- Mózes FE, Lee JA, Vali Y, et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. *Lancet Gastroenterol Hepatol.* 2023 Jun 5:S2468-1253(23)00141-3.
- Rosso C, Caviglia GP, Birolo G, et al. Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease. *Clin Gastroenterol Hepatol.* 2023 May 4:S1542-3565(23)00324-5.
- Armandi A, Bugianesi E. Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease: Cardiovascular Diseases. *Clin Liver Dis.* 2023 May;27(2):239-250.
- Armandi A, Caviglia GP, Abdulle A, et al. Prognostic Value of Simple Non-Invasive Tests for the Risk Stratification of Incident Hepatocellular Carcinoma in Cirrhotic Individuals with Non-Alcoholic Fatty Liver Disease. *Cancers (Basel).* 2023 Mar 8;15(6):1659.
- Armandi A, Rosso C, Younes R, et al. Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. *J Clin Med.* 2023 Jan 13;12(2):650.
- Armandi A, Colombo G, Rosso C, et al. The Predictive Role of Extracellular NAPRT for the Detection of Advanced Fibrosis in Biopsy-Proven Non-Alcoholic Fatty Liver Disease. *Int J Mol Sci.* 2023 Jan 7;24(2):1172.
- Perez-Diaz-Del-Campo N, Castelnuovo G, Caviglia GP, et al. Role of Circadian Clock on the Pathogenesis and Lifestyle Management in Non-Alcoholic Fatty Liver Disease. *Nutrients.* 2022 Nov 27;14(23):5053.

- Armandi A, Rosso C, Troshina G, et al. Changes in Liver Stiffness and Markers of Liver Synthesis and Portal Hypertension following Hepatitis C Virus Eradication in Cirrhotic Individuals. *Biology (Basel)*. 2022 Aug 2;11(8):1160.
- Caviglia GP, Nicolosi A, Abate ML, et al. Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease. *Curr Oncol*. 2022 Jul 31;29(8):5457-5465.
- Saponaro C, Sabatini S, Gaggini M, et al. Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals. *Liver Int*. 2022 Nov;42(11):2418-2427.
- Michel M, Labenz C, Wahl A, et al. Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV. *AIDS*. 2022 Oct 1;36(12):1665-1674.
- Armandi A, Rosso C, Nicolosi A, et al. Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease. *J Clin Med*. 2022 Jan 27;11(3):635.
- Labenz C, Toenges G, Zheng MH, et al. Derivation and validation of the NAFLD Cirrhosis Score (NCS) to distinguish bridging fibrosis from cirrhosis. *Eur J Intern Med*. 2022 Jan 17:S0953-6205(21)00413-1.
- Armandi A, Schattenberg JM. NAFLD and NASH: The Metabolically Diseased Liver. *Handb Exp Pharmacol*. 2021 Nov 23.
- Armandi A, Rosso C, Caviglia GP, et al. The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review. *Front. Endocrinol*. 12:716533.
- Rivera-Esteban J, Armandi A, Augustin S, et al. Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis. *Liver Int*. 2021 Sep;41(9):1999-2008.
- Labenz C, Kostev K, Armandi A, et al. Impact of thyroid disorders on the incidence of non-alcoholic fatty liver disease in Germany. *United European Gastroenterol J*. 2021 Jul 20;9(7):829-36.
- Armandi A, Schattenberg JM. Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches. *Nutrients*. 2021 Jun 8;13(6):1977.
- Armandi A, Bugianesi E. Natural history of NASH. *Liver Int*. 2021 Jun;41 Suppl 1(Suppl 1):78-82.
- Younes R, Caviglia GP, Govaere O, et al. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. *J Hepatol*. 2021 Oct;75(4):786-794.
- Caviglia GP, Armandi A, Rosso C, et al. Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. *Cancers (Basel)*. 2021 May 11;13(10):2305.
- Mózes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. *Gut*. 2021 May 17:gutjnl-2021-324243.
- Selvaraj EA, Mózes FE, Jayaswal ANA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. *J Hepatol*. 2021 Oct;75(4):770-785.
- Armandi A, Schattenberg JM. Editorial: the polygenic risk of cirrhosis development. *Aliment Pharmacol Ther*. 2021 Apr;53(7):849-850.
- Armandi A, Rosso C, Caviglia GP, et al. Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. *Metabolites* 11(3), March 2021.

- Younes R, Govaere O, Petta S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? *Gut*. 2021 Feb 4;gutjnl-2020-322564.
- Kazankov K, Rosso C, Younes R, et al. Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease. *Front Med (Lausanne)*. 2020 Dec 18;7:616212.
- Armandi A, Schattenberg JM. NAFLD between genes and environment: what drives fibrogenesis? *Gut*. 2020 Aug 5;gutjnl-2020-321964.
- Younes R, Govaere O, Petta S, et al. Presence of serum antinuclear antibodies does not impact long-term outcomes in Nonalcoholic Fatty Liver Disease. *Am J Gastroenterol* 2020 May 25.

Other information:

- 01/10/2022: Speaker at “Speakers’ Corner” for the Event “Unight: Notte Europea delle Ricercatrici e dei Ricercatori 2022” with the speech “La malattia da fegato grasso: prevenzione e trattamento”
- 22/02/2022: ICH Good Clinical Practice E6 (R2)
- English Language: C2 (Writing, Reading, Speaking) (Cambridge Certificate of Proficiency in English)
- German Language: A2 (Writing, Reading, Speaking) (Goethe-Institut Torino)